Business
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both
About this update from Adial Pharmaceuticals, Inc
[{"type":"text","content":"Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both European and U.S. regulatory agencies Actively exploring potential partnership opportunities for AD04 Ended second quarter with cash and cash equivalents of $9.2 million CHARLOTTESVILLE, Va., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2022. William Stilley, Adial’s Chief Executive Officer, stated, “We recently reported successful results from the ONWARD trial, our Phase 3 clinical study evaluating the efficacy, safety and tolerability of AD04 in patients with Alcohol Use Disorder (“AUD”) and selected polymorphisms in the serotonin transporter and receptor genes. The results showed that AD04 achieved a statistically significant mean reduction in heavy drinking days among the pre-specified group of “heavy drinkers” (avg.","length":1617,"tagName":"div"}]